BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38296517)

  • 21. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
    Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
    J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
    Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
    J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis.
    Leppelmann KS; Mooradian MJ; Ganguli S; Uppot RN; Yamada K; Irani Z; Wehrenberg-Klee EP; Zubiri L; Reynolds KL; Arellano RS; Hirsch JA; Sullivan RJ; Fintelmann FJ
    J Vasc Interv Radiol; 2021 Feb; 32(2):187-195. PubMed ID: 33353814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall.
    Höckel M; Sclenger K; Hamm H; Knapstein PG; Hohenfellner R; Rösler HP
    Cancer; 1996 May; 77(9):1918-33. PubMed ID: 8646694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
    Ozluk AA; Karateke M; Sanli UA; Karaca B
    Melanoma Res; 2023 Oct; 33(5):417-421. PubMed ID: 37276020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
    Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F
    Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
    Hosokawa S; Ichihara E; Bessho A; Harada D; Inoue K; Shibayama T; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 Feb; 51(2):279-286. PubMed ID: 33049757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade.
    Klemen ND; Court CM; Fernandes MC; Walch HS; Chatila WK; Saadat LV; Maron S; Crane C; Shia J; Cercek A; Gönen M; Schultz ND; Garcia Aguilar J; Jarnagin WR; D'Angelica MI
    Ann Surg Oncol; 2022 Dec; 29(13):8373-8382. PubMed ID: 35930112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
    Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
    Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
    Knisely A; Ahmed J; Stephen B; Piha-Paul SA; Karp D; Zarifa A; Fu S; Hong DS; Rodon Ahnert J; Yap TA; Tsimberidou AM; Alshawa A; Dumbrava EE; Yang Y; Song J; Meric-Bernstam F; Jazaeri AA; Naing A
    Cancer; 2024 Feb; 130(3):400-409. PubMed ID: 37864520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
    Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
    Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
    Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
    Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
    Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
    Adileh M; Yuval JB; Huang S; Shoushtari AN; Quezada-Diaz F; Pappou EP; Weiser MR; Garcia-Aguilar J; Smith JJ; Paty PB; Nash GM
    Dis Colon Rectum; 2021 May; 64(5):555-562. PubMed ID: 33939387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).
    Arians N; Foerster R; Rom J; Uhl M; Roeder F; Debus J; Lindel K
    Radiat Oncol; 2016 Mar; 11():44. PubMed ID: 26988089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.